)
)
Opiant Pharmaceuticals Investor Relations Material
Latest events
Q2 2022
Opiant Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Opiant Pharmaceuticals Inc
Access all reports
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company's lead product candidate is naloxone nasal spray that is in Phase III clinical trial for the treatment of opioid overdose. It also engages in developing temporary user-based treatment targeting at treating binge eating disorder (BED); as well as nasal treatments for other addictive/compulsive behaviors and disorders.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
OPNT
Country
🇺🇸 United States